Hans Bhatt

Hans Bhatt played a central role in the development and clinical translation of blinatumomab, the first FDA-approved bispecific T cell engager antibody, which has revolutionized the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. His research characterized the mechanism by which blinatumomab redirects T cells to kill CD19-expressing cancer cells with extraordinary potency. He led pivotal clinical trials that demonstrated remarkable complete remission rates in ALL patients who had exhausted other treatment options. His work established the BiTE antibody format as a validated cancer treatment modality.